These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20920993)

  • 41. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
    Gualberto A; Pollak M
    Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer.
    Sipos F; Székely H; Kis ID; Tulassay Z; Műzes G
    World J Gastroenterol; 2017 Dec; 23(46):8109-8119. PubMed ID: 29290648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
    Hewish M; Chau I; Cunningham D
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the insulin growth factor receptor 1.
    Arnaldez FI; Helman LJ
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):527-42, vii-viii. PubMed ID: 22520978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting insulin-like growth factor type 1 receptor in cancer therapy.
    Atzori F; Traina TA; Ionta MT; Massidda B
    Target Oncol; 2009 Dec; 4(4):255-66. PubMed ID: 19876700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Tyrosine kinase receptor-mediated signal transduction and cancer treatment].
    Zhu XF; Liu ZC; Zeng YX
    Yao Xue Xue Bao; 2002 Mar; 37(3):229-34. PubMed ID: 12579770
    [No Abstract]   [Full Text] [Related]  

  • 47. Minireview: Were the IGF Signaling Inhibitors All Bad?
    Beckwith H; Yee D
    Mol Endocrinol; 2015 Nov; 29(11):1549-57. PubMed ID: 26366975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.
    Zha J; O'Brien C; Savage H; Huw LY; Zhong F; Berry L; Lewis Phillips GD; Luis E; Cavet G; Hu X; Amler LC; Lackner MR
    Mol Cancer Ther; 2009 Aug; 8(8):2110-21. PubMed ID: 19671761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin-like growth factor receptor inhibitors: baby or the bathwater?
    Yee D
    J Natl Cancer Inst; 2012 Jul; 104(13):975-81. PubMed ID: 22761272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IGF1R and c-met as therapeutic targets for colorectal cancer.
    Shali H; Ahmadi M; Kafil HS; Dorosti A; Yousefi M
    Biomed Pharmacother; 2016 Aug; 82():528-36. PubMed ID: 27470393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted therapy for solid tumors: current status.
    Zureikat AH; McKee MD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The type 1 insulin-like growth factor receptor pathway.
    Chitnis MM; Yuen JS; Protheroe AS; Pollak M; Macaulay VM
    Clin Cancer Res; 2008 Oct; 14(20):6364-70. PubMed ID: 18927274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy.
    Werner H; Sarfstein R; Bruchim I
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1101-1112. PubMed ID: 31731883
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment.
    Bohula EA; Playford MP; Macaulay VM
    Anticancer Drugs; 2003 Oct; 14(9):669-82. PubMed ID: 14551500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.
    Shigyo M; Kuboyama T; Sawai Y; Tada-Umezaki M; Tohda C
    Sci Rep; 2015 Jul; 5():12055. PubMed ID: 26170015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Research progress on the relationship between insulin-like growth factor-I and lung cancer].
    Liu Z; Yue W; Li Q
    Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):642-7. PubMed ID: 20681455
    [No Abstract]   [Full Text] [Related]  

  • 57. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.
    Akil H; Perraud A; Jauberteau MO; Mathonnet M
    World J Gastroenterol; 2016 Jan; 22(2):490-500. PubMed ID: 26811602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer.
    Kasprzak A
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor tyrosine kinase inhibitors in thyroid cancer.
    Castellone MD; Carlomagno F; Salvatore G; Santoro M
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1023-38. PubMed ID: 19041829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?
    Subbiah V; Angelo LS; Kurzrock R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1471-7. PubMed ID: 21936711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.